Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nadia Zalunardo is active.

Publication


Featured researches published by Nadia Zalunardo.


American Journal of Transplantation | 2009

The Pregnancy Rate and Live Birth Rate in Kidney Transplant Recipients

John S. Gill; Nadia Zalunardo; Caren Rose; Marcello Tonelli

Fertility is one of the potential benefits for women undergoing kidney transplantation; however, population‐based information about the likelihood of pregnancy and successful fetal outcome is not available. In this observational study of 16 195 female kidney transplant recipients aged 15–45 years in the United States between 1990 and 2003, we determined the pregnancy rate and live birth rate using Medicare claims data from the first three posttransplant years. The pregnancy rate was 33 per thousand female transplant recipients between 1990 and 2003 and progressively declined from 59 in 1990 to 20 in 2000. The live birth rate between 1990 and 2003 was 19 per thousand female transplant recipients and declined in parallel with the pregnancy rate. Despite a decrease in therapeutic abortions over time, the proportion of pregnancies resulting in fetal loss (45.6%) remained constant during the study due to an increase in spontaneous abortions and other causes of fetal loss. The pregnancy rate in kidney transplant recipients was markedly lower and declined more rapidly than reported in the general American population during the same period. The live birth rate was substantially lower than reported in voluntary registries of transplant recipients, and the proportion of pregnancies resulting in unexpected fetal loss increased over time.


Advances in Health Sciences Education | 2012

Comparing the use of global rating scale with checklists for the assessment of central venous catheterization skills using simulation

Irene W. Y. Ma; Nadia Zalunardo; George Pachev; Tanya N. Beran; Melanie Brown; Rose Hatala; Kevin McLaughlin

The use of checklists is recommended for the assessment of competency in central venous catheterization (CVC) insertion. To explore the use of a global rating scale in the assessment of CVC skills, this study seeks to compare its use with two checklists, within the context of a formative examination using simulation. Video-recorded performances of CVC insertion by 34 first-year medical residents were reviewed by two independent, trained evaluators. Each evaluator used three assessment tools: a ten-item checklist, a 21-item checklist, and a nine-item global rating scale. Exploratory principal component analysis of the global rating scale revealed two factors, accounting for 84.1% of the variance: technical ability and safety. The two checklist scores correlated positively with the weighted factor score on technical ability (0.49 [95% CI 0.17–0.71] for the 10-item checklist; 0.43 [95% CI 0.10–0.67] for the 21-item checklist) and negatively with the weighted factor score on safety (−0.17 [95% CI −0.48–0.18] for the 10-item checklist; −0.13 [95% CI −0.45–0.22] for the 21-item checklist). A checklist score of <80% was strong indication of incompetence. However, a high checklist score did not preclude incompetence. Ratings using the global rating scale identified an additional 11 candidates (32%) who were deemed incompetent despite scoring >80% on both checklists. All these candidates committed serious errors. In conclusion, the practice of universal adoption of checklists as the preferred method of assessment of procedural skills should be questioned. The inclusion of global rating scales should be considered.


Transplantation | 2006

The older living kidney donor: Part of the solution to the organ shortage.

John S. Gill; Jagbir Gill; Caren Rose; Nadia Zalunardo; David Landsberg

Background. Strategies to increase kidney transplantation are urgently needed. Methods. We studied all (n=73,073) first kidney-only transplant recipients in the United States between 1995 and 2003 to determine the incidence and outcomes of living donor transplantation as a function of donor age. Because 90% of living donors were <55 years, we defined older living donors as ≥55 years. Factors associated with transplantation from older living donors and the association of living donor age with allograft function and survival were determined. Results. Recipients of older age, female gender, white race, and preemptive transplants had higher odds of older living donor transplantation. Older living donor transplantation was more likely from spousal donors rather than blood relatives, and more likely when a husband was the donor. The glomerular filtration rate (GFR) one year after transplantation decreased with increasing donor age (P<0.001). Graft survival from living donors ≥55 years was 85% and 76% at three and five years (compared to 89% and 82% with living donors <55 years, and 82% and 73% with deceased donors <55 years). In a multivariate model, the risk of graft loss with living donors 55–64 years was similar to that with deceased donors <55 years, while recipients from living donors 65–69 years (HR=1.3, 95% CI: 1.1–1.7) and >70 years (HR=1.7, 95% CI: 1.1–2.6) had a higher relative risk of graft loss. Conclusions. Outcomes are excellent with living donors <65 years. Expanded use of older living donors may help meet the demand for transplantation.


Journal of The American Society of Nephrology | 2007

Prevention of Sepsis during the Transition to Dialysis May Improve the Survival of Transplant Failure Patients

Olwyn Johnston; Nadia Zalunardo; Caren Rose; John S. Gill

Dialysis patients are at risk for sepsis, and the risk may be even higher among transplant failure patients because of previous or ongoing immunosuppression. The incidence and the consequences of sepsis as defined by International Classification of Diseases, Ninth Revision, Clinical Modification hospital discharge diagnoses codes were determined among 5117 patients who initiated dialysis after transplant failure between 1995 and 2004 in the United States. The overall sepsis rate was 11.8 per 100 patient years (95% confidence interval [CI] 11.5 to 12.1). Sepsis was highest in the first 6 mo after transplant failure (35.6 per 100 patient years [95% CI 29.4 to 43.0] between 0 to 3 mo after transplant failure; 19.7 per 100 patient years [95% CI 17.2 to 22.5] between 3 to 6 mo after transplant failure). In comparison, the sepsis rate among incident dialysis patients between 3 and 6 mo after dialysis initiation was 7.8 per 100 patient years (95% CI 7.3 to 8.3), whereas the sepsis rate among transplant recipients between 3 and 6 mo after transplantation was 5.4 per 100 patient years (95% CI 4.9 to 5.9). Patients who were > or =60 yr, obese patients, patients with diabetes, and patients with a history or peripheral vascular disease or congestive heart failure were at risk for sepsis. Transplant nephrectomy was not associated with septicemia. The role of continued immunosuppression and vascular access creation was not assessed and should be addressed in future studies. In a multivariate analysis, patients who were hospitalized for sepsis had an increased risk for death (hazard ratio 2.93; 95% CI 2.64 to 3.24; P < 0.001). Strategies to prevent sepsis during the transition from transplantation to dialysis may improve the survival of patients with allograft failure.


American Journal of Kidney Diseases | 2014

Timing of Arteriovenous Fistula Creation in Patients With CKD: A Decision Analysis

Steven M. Shechter; M. Reza Skandari; Nadia Zalunardo

BACKGROUND The optimal time for arteriovenous fistula (AVF) referral is uncertain. Improving the timeliness of referral may reduce central venous catheter (CVC) use. STUDY DESIGN Monte Carlo simulation model. SETTING & POPULATION Patients with chronic kidney disease (CKD) followed up in a multidisciplinary clinic, overall and stratified by age. MODEL, PERSPECTIVE, & TIMEFRAME Decision analysis, patient, patients lifetime. INTERVENTION AVF referral, using 1 of 2 strategies: refer when hemodialysis is anticipated to begin within a certain time frame or refer when estimated glomerular filtration rate (eGFR) drops below a certain threshold. OUTCOMES A range of values for each strategy are compared to each other with respect to incident vascular access type (AVF or CVC), percentage of patients with an unnecessary AVF creation, and life expectancy after dialysis therapy initiation. RESULTS A 15-month referral time frame gave 34% with incident CVCs, 14% with unnecessary AVFs, and a life expectancy of 1,751 days. Time frames of 12-18 months performed similarly. Referral at eGFR of 20 mL/min/1.73 m(2) gave 38% with incident CVCs, 20% with unnecessary AVFs, and life expectancy of 1,742 days. Using an eGFR threshold of 15 mL/min/1.73 m(2), 10% had an unnecessary AVF. Policy performance was affected by CKD progression rate and age. For fast progressors (ΔeGFR = -7mL/min/1.73 m(2) per year), referral at eGFR of 25 mL/min/1.73 m(2) achieved a similar incident CVC percentage (~40%) as referral at 15 mL/min/1.73 m(2) in slower progressors (ΔeGFR = -2.78 mL/min/1.73 m(2) per year). For patients aged 70-80 and 80-90 years, time frames of 15-18 months yielded 16%-22% with unnecessary AVFs (vs 9%-11% in 50- to 60-year-olds); an eGFR threshold strategy of 20 mL/min/1.73 m(2) yielded 24% unnecessary AVFs in 80- to 90-year-olds versus 16% in 50- to 60-year-olds. LIMITATIONS Our model does not consider patients with nonlinear CKD progression or acute kidney injury. We did not include arteriovenous grafts or consider cost or quality of life. CONCLUSIONS In general, AVF referral within about 12 months of the estimated time to dialysis performed best among time frame strategies, and referral at eGFR < 15-20 mL/min/1.73 m(2) performed best among threshold strategies. The timing of referral should also be guided by the individual rate of CKD progression. Elderly patients with CKD could be referred later to reduce the risk of creating an AVF that is never used.


Nephrology Dialysis Transplantation | 2014

Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort

Adeera Levin; Claudio Rigatto; Brendan J. Barrett; François Madore; Norman Muirhead; Daniel T. Holmes; Catherine M. Clase; Mila Tang; Ognjenka Djurdjev; Mohsen Agharazii; L'Hôtel-Dieu de Québec; Ayub Akbarii; Paul E. Barre; Susan Cooper; Brian Forzley; Serge H. Cournoyer; Janis M. Dionne; Sandra Donnelly; Brenda R. Hemmelgarn; Paul Keown; Nadia Zalunardo; Charmaine Lok; Louise Moist; Bharat Nathoo; Malvinder Parmar; Martine Leblanc; Steven D. Soroka; Siva Thanamayooran; Sheldon W. Tobe; Karen Yeates

BACKGROUND Newer biomarkers, reflective of biological processes, such as inflammation and fibrosis, cardiac stretch or damage and vascular health may be useful in understanding clinical events in chronic kidney disease (CKD). We assessed whether these newer biomarkers, alone or as a panel, improve risk prediction for renal replacement therapy or death, over and above conventional clinical, demographic and laboratory variables. METHODS We conducted a prospective observational Canadian cohort study in 2544 CKD patients with estimated glomerular filtration rate (eGFR) of 15-45 mL/min/1.73 m(2), under nephrology care, in urban and rural centers. We measured traditional clinical and laboratory risk factors, as well as newer biomarkers: cystatin C, high sensitivity c-reactive protein (hsCRP), interleukin 6 (IL6), transforming growth factor β1 (TGFβ1), fibroblast growth factor 23 (FGF23), N-terminal probrain natriuretic peptide (NT-proBNP), troponin I and asymmetric dimethylarginine (ADMA). Key outcomes were renal replacement therapy (RRT, dialysis or transplantation) and death, during the first year follow-up after enrollment: a time point important for clinical decision-making for patients and providers. RESULTS Newer biomarkers do not improve the prediction of RRT, when added to conventional risk factors such as eGFR, urine albumin to creatinine ratio, hemoglobin, phosphate and albumin. However, in predicting death within 1 year, cystatin C, NT-proBNP, hsCRP and FGF23 values significantly improved model discrimination and reclassification: c statistic increased by absolute 4.3% and Net Reclassification Improvement for categories of low, intermediate and high risk at 11.2%. CONCLUSIONS Our findings suggest that the addition of newer biomarkers may be useful in predicting death in patients with established CKD within a 1-year timeframe. This information may be useful in informing prognosis and redirect resources to serve patients at higher risk to improve outcomes and sustainability of the nephrology care system.


Nephrology Dialysis Transplantation | 2011

Proliferative glomerulonephritis with monoclonal IgG deposits secondary to chronic lymphocytic leukemia. Report of two cases

Sean J. Barbour; Monica Beaulieu; Nadia Zalunardo; Alex B. Magil

Proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) is a recently described entity that is only rarely associated with a hematological or lymphoproliferative malignancy. We describe the cases of two men with preexisting chronic lymphocytic leukemia (CLL) who developed endocapillary proliferative glomerulonephritis with nonorganized monoclonal IgG(1) deposits. One biopsy also showed CLL infiltration of the cortex. Both patients were treated with rituximab in addition to cyclophosphamide in one case and fludarabine in the other with significant improvement of their renal disease and CLL. This report provides additional evidence to support the use of rituximab in the therapy of CLL-associated PGNMID.


Nephrology Dialysis Transplantation | 2011

Dedication of a nurse to educating suboptimal haemodialysis starts improved transition to independent modalities of renal replacement therapy

Jennifer Hanko; Jacek Jastrzebski; Cheryl Nieva; Leigh White; Guiyun Li; Nadia Zalunardo

BACKGROUND Haemodialysis (HD) initiation is unplanned in up to 50% of patients, mainly due to late diagnosis and/or late nephrology referral. In these patients, time does not permit the multidisciplinary predialysis care that is associated with increased independent renal replacement therapy (RRT) modality choice and better access to kidney transplantation. We established a Renal Triage Nurse (RTN) position to educate suboptimal HD starts and to facilitate transition to independent modalities of RRT. METHODS Adult patients starting HD from 1 January 2005 to 31 December 2008 with < 180 days nephrology follow-up and surviving at least 180 days were included (suboptimal HD starts). The RTN educated suboptimal HD starts beginning in December 2006. Patients initiating RRT via the multidisciplinary predialysis clinic (MPC) were included for comparison. Multivariable logistic regression was used to determine the association between being seen by the RTN and achieving independent modalities of RRT. RESULTS There were 176 patients: 78 suboptimal HD starts (38 of these were educated by the RTN) and 98 patients initiated RRT after a minimum 180-day follow-up at the MPC. Of the RTN patients, 27.8% switched to independent RRT modalities (peritoneal dialysis n = 7, home haemodialysis n = 1, transplant n = 2). RTN patients were more likely to live alone (33.3% versus 10.8%, P = 0.02) and to have cerebrovascular disease (25.0% versus 7.1%, P = 0.03); however, adjusting for these variables, suboptimal HD starts seen by the RTN were more likely to transition to independent RRT (OR 3.75, 95% CI 1.08-13.05) than those not seen. The proportion starting on an independent modality via the MPC was 39.8%. The RTN achieved a rate of independent RRT not statistically different to that observed in patients starting RRT via the MPC (OR 0.74, 95% CI 0.19-2.94 in multivariable analysis). CONCLUSIONS Addition of the RTN to the HD care team facilitated transition to independent modalities of RRT in suboptimal HD starts. This standardized approach to the care of such patients should be considered in HD units where suboptimal HD starts are common.


Clinical and Experimental Nephrology | 2007

Conservative outpatient renoprotective protocol in patients with low GFR undergoing contrast angiography: a case series

Paul Komenda; Nadia Zalunardo; Shelley Burnett; Christpher Buller; Paul Taylor; John A. Duncan; Ogjenenka Djurdjev; Adeera Levin

BackgroundThe correct strategy to prevent radiocontrast-induced nephropathy (CIN) in high-risk patients going for cardiac angiography is widely debated in the literature. It is well known that chronic kidney disease (CKD) patients with lower estimated glomerular filtration rates (eGFRs) at baseline are at the greatest risk for a significant loss in kidney function, or even dialysis after a contrast load. For this reason potentially life-saving procedures such as angiography are sometimes withheld or delayed.MethodsWe describe a case series of 31 well-characterized patients with CKD who underwent cardiac or peripheral vessel angiography, and patients with renal artery stenosis (RAS) who underwent angioplasty and stenting. All were treated with a standardized outpatient protocol of withholding their diuretics and angiotensin-converting enzyme (ACE) inhibitors (ACEs)/angiotensin receptor blockers (ARBs) the day prior to and 2 days after the procedure, restarting the diuretic the day after the procedure and the ACE inhibitor/ARB after 2 days. Calcium channel blockers were prescribed for the 2 days prior to and 2 days after the procedure. Patients had bloodwork on days 2–3 and days 7–10 post-procedure.ResultsThe patients had a mean baseline creatinine of 214 µmol/l (SD = 123), ranging from 87 to 535 µmol/l. This corresponded to a mean baseline eGFR of 34 ml/min (SD = 15.8), ranging from a minimum of 12–59 ml/min. The mean age was 64 ± 13.8 years; 48% were male and 11 (35.5%) were diabetic. All patients enrolled had a baseline eGFR of less than 60 ml/min as calculated by the Modification of Diet in Renal Disease (MDRD) formula. Based on pre-procedure CKD stage, 21 (68%) were stage 3 (eGFR 30–60 ml/min), 5 (16%) were stage 4 (eGFR 15–30 ml/min), and 6 (19%) were stage 5 (eGFR < 15 ml/min). No patient required urgent hemodialysis following their angiography. All patients have had a longitudinal follow up of 26 months, and none developed any change in the rate of progression from prior to procedure.ConclusionsThis case series provides data in support of a conservative, outpatient-based approach for high-risk CKD patients going for cardiac angiography. This protocol warrants further study in randomized control trials.


American Journal of Transplantation | 2016

Timing of Pregnancy After Kidney Transplantation and Risk of Allograft Failure

Caren Rose; Jagbir Gill; Nadia Zalunardo; Olwyn Johnston; Anita Mehrotra; John S. Gill

The optimal timing of pregnancy after kidney transplantation remains uncertain. We determined the risk of allograft failure among women who became pregnant within the first 3 posttransplant years. Among 21 814 women aged 15–45 years who received a first kidney‐only transplant between 1990 and 2010 captured in the United States Renal Data System, n = 729 pregnancies were identified using Medicare claims. The probability of allograft failure from any cause including death (ACGL) at 1, 3, and 5 years after pregnancy was 9.6%, 25.9%, and 36.6%. In multivariate analyses, pregnancy in the first posttransplant year was associated with an increased risk of ACGL (hazard ratio [HR]: 1.18; 95% confidence interval [CI] 1.00, 1.40) and death censored graft loss (DCGL) (HR:1.25; 95% CI 1.04, 1.50), while pregnancy in the second posttransplant year was associated with an increased risk of DCGL (HR: 1.26; 95% CI 1.06, 1.50). Pregnancy in the third posttransplant year was not associated with an increased risk of ACGL or DCGL. These findings demonstrate a higher incidence of allograft failure after pregnancy than previously reported and that the increased risk of allograft failure extends to pregnancies in the second posttransplant year.

Collaboration


Dive into the Nadia Zalunardo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Caren Rose

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

John S. Gill

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Monica Beaulieu

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Steven M. Shechter

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge